Oncotarget

Research Papers:

MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer

María-José de Miguel-Luken, Manuel Chaves-Conde, Verónica de Miguel-Luken, Sandra Muñoz-Galván, José Luis López-Guerra, Juan C. Mateos, Jerónimo Pachón, David Chinchón, Vladimir Suarez and Amancio Carnero _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2015; 6:12625-12636. https://doi.org/10.18632/oncotarget.3470

Metrics: PDF 925 views  |   HTML 1288 views  |   ?  


Abstract

María-José de Miguel-Luken1, Manuel Chaves-Conde1, Verónica de Miguel-Luken2, Sandra Muñoz-Galván3, José Luis López-Guerra4, Juan C. Mateos4, Jerónimo Pachón4, David Chinchón5, Vladimir Suarez4 and Amancio Carnero3

1 Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain

2 University of Málaga, Málaga, Spain

3 Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Consejo Superior de Investigaciones Científicas, Seville, Spain

4 Department of Radiation Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain

5 Department of Pathology, Hospital Universitario Virgen del Rocío, Seville, Spain

Correspondence to:

Amancio Carnero, email:

Keywords: MAP17, ROS, SGLT, biomarker, larynx/laryngeal cancer

Received: December 02, 2015 Accepted: January 20, 2015 Published: February 28, 2015

Abstract

Larynx cancer organ preservation treatments with chemo and radiotherapy have substantially improved laryngoesophageal dysfunction-free survival. However, both of them lead to a high incidence of acute and chronic toxicities and a significant number of patients relapse. To date, there is no evidence available to establish the group of patients that may benefit from preservation approaches and clinical criteria such as primary tumor extension or pretreatment tracheotomy are not validated. MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. The tumoral behavior induced by MAP17 is associated with reactive oxygen species production in which SGLT1 seems involved. In this study we found that the levels of MAP17 were related to clinical findings and survival in a cohort of 58 patients with larynx cancer. MAP17 expression is associated with overall survival (p<0.001) and laryngoesophageal dysfunction-free survival (p=0.002). Locoregional control in patients with high MAP17 showed better outcomes than those with low MAP17 (p=0.016). Besides, a positive correlation was observed between MAP17 expression and SGLT (p=0.022) and the combination of high levels of MAP17/SGLT also led to an increased overall survival (p=0,028). These findings suggest that MAP17, alone or in combination with SGLT1, may become a novel predictive biomarker for laryngeal carcinoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3470